Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Athira Shareholders Vote “FOR” All of Athira’s Highly Qualified Director Nominees
05 mai 2022 12h04 HE
|
Athira Pharma, Inc.
Joins Institutional Shareholder Services in Recommending a Vote on Athira’s WHITE Proxy Card Athira Urges Shareholders to Vote “FOR” Athira’s Highly Qualified, Independent Director Nominees – Joseph...
Athira Mails Letter to Shareholders Emphasizing the Company’s Strong Position and Qualified Board as it Enters Pivotal Chapter
05 mai 2022 08h00 HE
|
Athira Pharma, Inc.
Urges Shareholders to Vote “FOR” Athira’s Highly Qualified, Independent Director Nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE Proxy Card BOTHELL, Wash., May ...
Leading Independent Proxy Advisory Firm ISS Recommends that Athira Shareholders Vote on Athira’s WHITE Proxy Card
04 mai 2022 18h46 HE
|
Athira Pharma, Inc.
Athira Urges Shareholders to Vote “FOR” Athira’s Highly Qualified, Independent Director Nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE Proxy Card Today BOTHELL,...
Athira Files Investor Presentation Highlighting Successful Execution of its Strategy and Highly Qualified Board and Leadership
26 avr. 2022 08h00 HE
|
Athira Pharma, Inc.
Urges shareholders to vote “FOR” Athira’s highly qualified, independent director nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE proxy card BOTHELL, Wash., April ...
Athira Mails Letter to Shareholders Highlighting the Strength of its Board and Record of Deliberate Board Refreshment
20 avr. 2022 09h02 HE
|
Athira Pharma, Inc.
Urges shareholders to vote “FOR” Athira’s highly qualified, independent director nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE proxy card BOTHELL, Wash., April 20,...
Athira Files Definitive Proxy Statement and Mails Letter to Shareholders
05 avr. 2022 16h04 HE
|
Athira Pharma, Inc.
Urges shareholders to vote “FOR” Athira’s highly qualified, independent director nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE proxy card Highlights successful...
Athira Pharma Doses First Subject in Phase 1 Clinical Trial of HGF/MET Positive Modulator, ATH-1020, an Orally Available Small Molecule for Neuropsychiatric Conditions
04 avr. 2022 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., April 04, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
Athira Pharma Highlights Strong Execution of Strategy and Positioning for the Future
30 mars 2022 12h12 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., March 30, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
Athira Pharma Reports Full Year 2021 Financial Results and Provides Clinical Update
24 mars 2022 16h05 HE
|
Athira Pharma, Inc.
On track to report topline data from ACT-AD Phase 2 Alzheimer’s disease study in 2Q22 Expect to complete enrollment in LIFT-AD Phase 3 Alzheimer’s disease study in 3Q22 Conference call today at 4:30...
Athira Pharma Announces Appointment of Dr. Michael A. Panzara to its Board of Directors
21 mars 2022 07h05 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., March 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...